Ani Pharmaceuticals Inc (ANIP) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ani Pharmaceuticals Inc  (NASDAQ: ANIP)


Ani Pharmaceuticals Inc's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Ani Pharmaceuticals Inc's ROA in the third quarter of 2026?
Ani Pharmaceuticals Inc achieved a return on average assets (ROA) of 7.76 % in its third quarter of 2026, this is above ANIP's average return on assets of -5.13%.
Ani Pharmaceuticals Inc assets over the 12 months ending in its third quarter of 2026 are valued at $1,484 million

ROA has improved compared to 7.38% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 118 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 951, from total ROA ranking in the second quarter of 2026 at 1249.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Total Assets Change 11.33 % 11.25 % 10.02 % 4.04 % 9.38 %
Y / Y Net Income Change 32.05 % 169.04 % 88.07 % - -
Net Income (TTM) in million 115 107 92 78 41
Return On Assets (TTM) 7.76 % 7.38 % 6.55 % 5.7 % 2.98 %
ANIP's Total Ranking # 951 # 1249 # 1585 # 2711 # 2832
Total Assets (TTM) in million 1,568 1,494 1,422 1,451 1,408
Seq. Total Assets Change 4.92 % 5.07 % -2.03 % 3.07 % 4.85 %
Seq. Net Income Change 52.82 % -22.01 % 7.28 % 3.28 % 211.35 %

ANIP's 5 Years Annual ROA >> Back to ANIP Management Effectiveness >> Compare ANIP ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 44
Sector # 119
Overall # 790

Return On Assets Statistics
High Average Low
22.05 %
-5.13 %
-91.83 %
(Dec 31 2014)   (Dec 31 2011)



  News about Ani Pharmaceuticals Inc Return on Assets ROA

ANI Pharmaceuticals Launches Combined Promethazine and Dextromethorphan Oral Solution for Enhanced Respiratory Reli...

ANI Pharmaceuticals, Inc. has announced the successful launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, a novel therapeutic solution designed for symptom management in respiratory ailments. This formulation delivers effective antitussive and antihistaminic effects, presenting a significant advancement for healthcare providers and patients alike. Respiratory illnesses remain a pivotal challenge in clinical management and patient health, often requiring effective symptomatic treatment. Promethazine Hydrochloride and Dextromethorphan Hydrobromide are well-documented compounds known for their respective roles as an antihistamine and cough suppressant. The recent introduction of their combined oral solution by ANI Pharmaceuticals marks a strategic step towards offering an optimized therapeutic option for both pediatric and adult patients.



Financial Statements
Ani Pharmaceuticals Inc's Assets $ 1,568 million ANIP's Balance sheet
Ani Pharmaceuticals Inc's Income $ 35 million Quarterly ANIP's Income Statement
ANIP's Income by Division See ANIP's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 12.21 % 41.94 % 18.99 % -1.49 % 67.31 %
Total Assets in million 1,440 1,284 904 760 772
Y / Y Net Income Change - - - - -
Net Income in million 78 -19 19 -48 -43
Annual Return On Assets 5.44 % -1.44 % 2.08 % -6.3 % -5.52 %

ANIP's 5 Years Annual ROA >> Back to ANIP Management Effectiveness >> Compare ANIP ROA to its Competitors



Comment on ANIP's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 5.44 % compared to prior year, due to annual net income growth of % to $78.34 million, while value of Ani Pharmaceuticals Inc's overall assets grew just by 12.21 % to $1,440.38 million, compared to $1,440.38 a year before.


More Return On Assets Ratios
ANIP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ANIP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ANIP's Competitors
Subscribers only: Roa for Ani Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Assets for ANIP's Customers

You may also want to know
ANIP's Roi ANIP's Inventory Turnover Ratio ANIP's Growth Rates ANIP's Dividend Comparisons
ANIP's Profitability Ratios ANIP's Asset Turnover Ratio ANIP's Dividend Growth
ANIP's Roe ANIP's Valuation Ratios ANIP's Financial Strength Ratios ANIP's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector ROA
Eli Lilly And Company  21.24 %
Iradimed Corporation  20.89 %
Resmed Inc   18.67 %
Alector Inc   18.37 %
Corcept Therapeutics Inc  18.09 %
Chemed Corporation  17.73 %
Halozyme Therapeutics Inc   17.26 %
Pro dex Inc   16.75 %
Denali Therapeutics Inc   16.42 %
Krystal Biotech Inc   15.48 %
West Pharmaceutical Services Inc   15.47 %
Dexcom Inc   15.47 %
Intuitive Surgical Inc   14.71 %
Vertex Pharmaceuticals Inc  14.16 %
Neurocrine Biosciences Inc   13.69 %
Illumina Inc   13.43 %
Healthcare Services Group Inc   12.79 %
Kiniksa Pharmaceuticals International Plc  12.64 %
Tenet Healthcare Corp  12.39 %
Hca Healthcare Inc   11.73 %
Carlisle Companies Incorporated  11.72 %
Regeneron Pharmaceuticals Inc   11.50 %
Lantheus Holdings Inc   11.43 %
Msa Safety Inc  11.01 %
Encompass Health Corporation  10.99 %
Inspire Medical Systems inc   10.89 %
Transmedics Group Inc   10.67 %
Bristol myers Squibb Company  10.47 %
Lemaitre Vascular Inc   10.28 %
Bio rad Laboratories Inc   9.88 %

Date modified: 2026-11-09T06:44:24+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.